Replay available

Ironwood Pharmaceuticals (NASDAQ:IRWD) Q4 2020 Earnings Call

Ironwood Pharmaceuticals (NASDAQ:IRWD) Q4 2020 earnings call, held 2021-02-17. Watch the replay and read the transcript on 6ix.

Wed, February 17, 2021 at 8:30 AMendedReplay
Ironwood Pharmaceuticals (NASDAQ:IRWD) Q4 2020 Earnings Call
Company
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Period
Q4 2020 earnings call
Date
Wed, Feb 17, 2021, 8:30 AM ET
Replay
Watch the replay on this page · 39 min
Results news release
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance · Wed, Feb 17, 2021

On 6ix: 6ix.com/event/ironwood-pharmaceuticals-inc-irwd-q4-2020-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Thank you for standing by and welcome to the Ironwood Pharmaceuticals fourth quarter and full year 2020 investor update conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1 on your telephone keypad. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, Meredith Faya. Thank you. Please go ahead.

0:28 Good morning and thanks for joining us for our fourth quarter and full year 2020 investor update. Our press release crossed the wire this morning and can be found on our website. Today's call and accompanying slides include forward-looking statements. Such statements involve risks and uncertainties that may cause actual results to differ materially. A discussion of these statements and risk factors is available on the current Safe Harbor Statement slide as well as under the heading Risk Factors in our quarterly report on Form 10-Q, for the quarter ended September 30, 2020 and in our future SEC filing. All forward-looking statements speak as of the date of this presentation, and we undertake no obligation to update such statements. Also included are non-GAAP financial measures, which should be considered only as a supplement to and on a substitute for superior to GAAP measures. To the extent applicable, please refer to the tables at the end of our press release for reconciliations of these measures to the most directly comparable GAAP measures.

1:22 During today's call, Mark Mallon, our CEO, will begin with an overview, followed by Tom McCourt, our president and incoming interim CEO, who will review our strategic priorities in commercial performance of LensF. Then Gina Konselman, our CFO, will review our 2020 financial results and provide guidance for 2021. And finally, Mike Shetzline, our chief medical officer, will provide an overview of our current focus on GI innovation. We will close with a Q&A session. We'll be referring to slides via the webcast. For those of you dialing in, please go to the event section of our website to access the webcast slides. With that, I'll turn the call over to Mark.

1:59 Thanks, Meredith. Good morning, everyone, and thanks for joining us today. Let me begin by saying how proud I am of the entire Ironwood team who truly showed their passion and commitment throughout 2020 to advance treatment for GI diseases and redefine the standard of care for GI patients. Their passion and mission-driven approach is one of the things that has most inspired me during my time with Ironwood. As I shared last week, deciding to leave Ironwood was indeed easy, but the chance to pursue certain passions of mine is really the right decision for me personally and for my family. I'm confident Ironwood will be in great hands with Tom as interim CEO while the board conducts its search. Tom has been an incredible colleague of mine for many years and a key member of the leadership team since joining Ironwood in 2009.

2:47 In addition to his many accomplishments over the years, he led the successful launch and commercialization of Linfez. Despite the challenges of the COVID-19 pandemic over the last year, Ironwood's business fundamentals and financials are strong. We believe the resilience and strength of Linzess combined with the continued profit and cash generation in 2020 provides a solid foundation for the future. I'm confident Ironwood is well positioned to deliver value for patients and shareholders. Turning to our 2020 performance, we began 2020 focused on our three core priorities to drive Linzess growth, advance our GI portfolio, and deliver sustainable profits. Munthez continues to be the prescription market leader within its category, demonstrating exceptional growth in the brand's eighth year since launch.

3:35 Additionally, Ironwood has now delivered its second consecutive year of profits and ended 2020 with over $360 million in cash, more than doubling our cash position from the end of 2019. Turning to our pipeline, the results from the 3718 and 7246 clinical programs were disappointing. These are two distinct programs that were being developed to treat high unmet medical needs and represented an opportunity to potentially help millions of patients. While these types of outcomes are not uncommon in drug development, they are certainly never easy, especially when they affect our own teammates, as these did with the recent workforce reduction. We were pleased to receive the approval of lenacletide S and D-A for overall abdominal symptoms data in adults with IBSC, as well as the progress of our ongoing pediatric studies.

4:24 With several GI diseases in desperate need of new therapies, continued scientific progress within this category, and our unique expertise and capabilities, the team is focused on finding and advancing innovative treatments for GI diseases. I'm proud of the strong foundation we've built together. All of you at Ironwood are true champions in the GI community, and I'm privileged to have worked alongside you. I look forward to following Ironwood as it seeks to drive continued success. With that, I'll turn it over to Tom. Tom?

4:59 Thanks, Mark, and good morning, everyone. I look forward to serving as the interim CEO following Mark's transition as we build on the strong foundation we have in place. Our path forward strategy begins with maximizing Lund's S. We believe there's substantial opportunity for continued growth and are working closely with our partner to deploy innovative commercial strategies in enhancing the clinical profile through lifecycle management. Second, we're focused on building an innovative GI development portfolio by pursuing assets that target serious organic GI diseases. We maintain a disciplined approach to exploring and assessing potential new assets including applying a focused set of criteria and a high bar for any potential deal that we may consider.

5:47 We believe our new refreshed approach has the potential to drive our business further and faster and with the potential for providing great benefit to patients we can serve. And third, we seek to continue to take a thoughtful and disciplined approach to capital allocation in an effort to continue generating sustainable profits and cash flow. We're steadfast in our mission and, importantly, remain focused on our goals of driving value to shareholders by bringing important medicines to patients and building a growing and successful business. Now let me turn to the commercial performance. In 2020, Linzess showed incredible strength and resilience in the face of the pandemic, further strengthening its position as the number one prescribed medicine in the U.S.

6:34 for the treatment of adults with IBSC and chronic constipation. Linzess prescription demand grew 8% in the fourth quarter and 9% for the full year 2020 year-over-year. This strong performance translated into full-year U.S. net sales of $931 million, a remarkable achievement. And we are seeing strong Linzess demand growth continuing into the first quarter, and while it's still early, we're very encouraged by the performance thus far. We believe Linzess remains on track to exceed a billion dollars in U.S. net sales with several additional opportunities to drive further growth. The brand hit all-time highs in new-to-brand prescriptions in the second half of 2020, reinforcing that patients and healthcare practitioners continue choosing Linzess for appropriate patients despite the pandemic-related limitations.

7:30 We also saw an increase in 90-day prescriptions as a percent of our total business. In the fourth quarter, 90-day prescription demand was 20% of our business versus 17% during the same time in 2019, meaning on average more total pills per prescription. The brand's success to date in the U.S. has come through consistent, strong execution of the commercial strategy that's grounded in three core fundamentals. Increasing awareness of Linzess among physicians, motivating appropriate patients to seek care and request Linzess, and securing broad payer access. Moving forward, we intend to continue to focus on these core fundamentals, but to execute in new ways in an effort to further maximize the Linzess potential.

8:19 First, to further support our clinical discussions with health care practitioners, we're working to strengthen the virtual selling capabilities we deployed in 2020 and create a hybrid selling model. We think this will be important capability for the future. In addition, we intend to build further awareness of the overall abdominal symptom data in adults with IBSC based on the FDA approved labeling update in 2020. We also intend to advance our efforts in telemedicine in light of the expansion of the use of telemedicine by patients and physicians. We're in the process of expanding our telemedicine efforts and capabilities and seeking to strengthen the impact in 2021.

9:04 Since launch, there has been a significant focus on establishing broad payer access. As the prescription market leader in its category, Linzess has wide unrestricted access, and we seek to maintain this status as a key growth driver for the brand. Lastly, we expect to advance additional lifecycle management efforts for Linaclotide. We believe we have a long runway to continue to grow, and we are currently evaluating opportunities for LinexGuide both with regard to new indications and new patient populations. With that, I'll turn the call over to Gina. Gina?

9:42 Thanks, Tom, and good morning, everyone. I am pleased to be able to highlight our strong financial performance for 2020 and provide our 2021 financial guidance. Please refer to our press release for our detailed financial information. First, touching on our 2020 financial performance. Ironwood total revenues in the fourth quarter of 2020 were $117 million, driven primarily by a 9% increase in U.S. collaboration revenue from Linzess year-over-year and $390 million for the full year, exceeding our 2020 revenue guidance. A reminder that 2019 revenues included $42 million in license and milestone payments and $49 million in sales of Limeclatide API recorded in 2019.

10:27 Beginning in 2020, we are no longer responsible for the supply of Linaclified API to our ex-US partners. API sales during this past year reflected the remaining API shipments to Astellas and AstraZeneca per our amended agreements. Regarding LINZEPS, US net sales were up 16% in the fourth quarter and 10% for the full year 2020 year over year. I'd like to briefly comment on commercial margin in the fourth quarter, as it was lower than we have seen in previous quarters. Thank you for joining us. Thank you for joining us today.

11:55 Turning now to Ironwood's profitability in cash.

11:58 For full year 2020, our profitability was driven by significantly higher LINZF net sales and lower operating expenses compared to 2019. Gap net income was $106 million and adjusted EBITDA was $161 million in 2020. Additionally, we generated $169 million in cash flow from operations and ended the year with $363 million in cash and investments. We are pleased to provide our full year 2021 financial guidance, in which we expect U.S. Linzess net sales growth of 3% to 5%. We anticipate net sales growth to be driven by high single-digit percent growth in Linzess prescription demand, continuing its momentum for 2020, offset by mid-single-digit percent price erosion resulting from certain contract changes going into effect this year. We expect total revenue of $370 to $385 million.

12:52 mainly driven by growth in U.S. collaboration revenues and inclusive of approximately $10 million that we anticipate from royalties, co-promotion, and other revenue. And lastly, we expect adjusted EBITDA of greater than $190 million with adjusted EBITDA continuing to be a proxy for cash generation as it was in 2020. We believe our continued financial performance, our current cash balance, and the numerous steps taken to strengthen our financial profile positions us well for 2021 and beyond. Delivering shareholder value is at the heart of successfully meeting our strategic priorities. This is a critical threshold for our investment decisions as we continue to invest thoughtfully into our business. Our capital allocation strategy is focused on Maximizing Lundesk As Tom mentioned earlier, we expect to continue to invest in opportunities to drive further growth in Lundesk.

13:45 This is our highest priority and where we believe we can create the most value today. We are also leveraging our GI expertise in an effort to build an innovative pipeline by pursuing inorganic opportunities to diversify our GI portfolio. And lastly, We expect to continue to explore ways to deploy any excess free cash, including the potential for opportunistic share repurchases. Before I turn it over to Mike, I want to briefly highlight our renewed strategy to build our GI pipeline. We are focused on diseases that are largely managed by GEs, prioritizing organic GI diseases with well-defined pathology and where we have an opportunity to accelerate development within shorter timelines.

14:33 In addition, we are focused on innovative clinical assets that already have demonstrated preliminary efficacy and safety. And finally, we seek to maintain our ability to deliver profits and cash as we have been doing. With that, I'll turn it over to Mike.

14:51 Thanks, Gina. I'll spend the last few minutes touching on the opportunities within the GI space and our own Ironwood 3200 program. We've been steadfast in our efforts to advance treatments for GI diseases over the past two years, and the learnings we've gained give us confidence in our fresh strategy to also explore earlier stage development opportunities in serious organic diseases. Through our recent assessment of the GI landscape, we've identified over 100 GI assets across more than 25 disease areas that fit our new focus strategy. Through these efforts, we prioritized eight disease areas with high unmet need and where we believe we can have the most impact. These areas where we've seen a lot of progress in the understanding of the disease, the pathophysiology, and the potential targets.

15:41 For example, two of the disease areas we're looking at are pancreatitis and celiac disease. Pancreatitis is a significant medical need since, unfortunately, today patients are still treated with IV fluids and pain management. with no approved therapies targeting the underlying pathology of their disease. Celiac disease, where the pathophysiology is very well defined and the mechanism is well understood and there are lots of opportunities to target new medications for suffering, for patients suffering from these diseases, still has no medical therapies. While these are just two examples, clearly there remains tremendous unmet need within GI. In conjunction with this strategy, we're also advancing 3300, a GCC agonist being developed for the potential treatment of visceral pain conditions such as bladder pain syndrome and endometriosis.

16:31 3300 is a stable and potent GCC agonist that provides a true opportunity to test the crosstalk hypothesis in humans. CrossTalk is a well-known biologic phenomenon where sensations or injury originating in one organ can cause altered sensation in a nearby organ because of overlapping nerve pathways. We believe this can result in enhanced pain perception affecting the bladder and reproductive organs in the pelvic area. We have strong preclinical data in a number of visceral pain models, including vaginal and bladder pain, that suggest the potential for GCC stimulation with 3300 to alleviate the visceral pain. We expect to submit an IMD application with the US FDA in the second half of 2021, putting us on track, if approved, to initiate a Phase I clinical trial with 3300 in early 2022.

17:25 We expect this trial will help us determine the asset's potential for further clinical development. I'll now turn it over to Mark for some closing comments before Q&A. Mark?

17:47 Sorry, I was on mute. Apologies, everyone. So thanks, Mike, for catching that, and thanks for the update on 3300. It's certainly an exciting opportunity for Ironwood. As you've heard from the team this morning, Ironwood has a significant opportunity ahead to advance our vision of becoming the leading GI-focused healthcare company in the U.S., and I want to thank the entire Ironwood team for a tremendous effort in putting patients at the forefront of everything we do. Thanks again for joining us this morning. Operator, Megan, we can now open the line for Q&A. Certainly. At this time, we would like to take any questions you may have for us today. To ask a question, please press star 1 on your telephone keypad. Our first question is from Martin Oster with Credit Suisse. Your line is open. Hi, Martin.

18:33 Hi, everyone. This is actually Mark on for Marty. Thanks for taking my question. I guess, too, for me, I was wondering if you might be able to provide a little more clarity on your 2021 guidance It looks like revenue guidance is roughly flat year over year, while you expect Linz S.U.S. net sales to grow 3% to 5%. Is that discrepancy due to higher AbbVie Ironwood commercial costs, or is there something else we need to consider? And I guess, are there any additional details you could provide on how we should think about these costs moving forward? And then the second question I have relates to, I believe Generic and Atiza entered the market the other month. I'm just curious if you could kind of speak to what impact you have seen since it entered the market, and has it resulted in any pressure on Linzest pricing?

19:26 And if so, how does that impact on pricing compared to your expectations coming into the year?

19:32 So thanks for the questions, Mark. Tina, can you take the first one? And Tom, maybe you can pick up the question I'm going to use.

19:39 Sure. Sure. I'm happy to. Thanks, Mark. So if I understood it correctly, I think you're asking about the decline in revenue despite the fact that we're guiding to increase Lindef's revenue. So maybe just a quick reminder that the Ironwood revenue includes a bit more than the collaboration revenue that we recognize from the Lindef collaboration with AbbVie. The other revenue, for instance, in 2020 included a small amount of API sales. We had just a wrap-up of the API sales to Astellas and AstraZeneca in 2020 from the restructured arrangements in 2019. We actually had significant revenue in 2019 related to those agreements and then a small amount in 2020. That's done now. At this point, it's wrapped up, and we're not expecting revenue to continue in 2020. So that's one part of it.

20:33 And the other part of it is related to the $10 million that I called out as part of the guidance. The $10 million is included in the overall Ironwood revenue, and it's actually down a bit year over year, or expected to be in 2021 versus 2020. And that is in part that we mentioned as well. In 2020, we received fixed payments plus royalties, and in 2021, going forward, we're expecting to only receive royalties.

21:14 You're absolutely right. Generic Ametiza is a single source. Generic is now available. I think as far as its impact, its market share has been eroding over time. Keep in mind, it was the market leader when we entered the market, and obviously really within the first 18 months, We were able to actually catch it and actually surpass it with regard to market share. It's important to remember these are very different molecules. The overall efficacy and tolerability looks quite different. The piece that has been driving Lindt's growth over time has been the high-level treatment satisfaction, both on the part of the physician and the patient.

21:59 As far as pricing pressure, I think it's important to remember we've been playing in a generic market since we launched with generic PEG. And so there's been multiple generic options available to patients. And I think it also is important to note that the far majority of patients still continue to be treated by OTCs even though they're not satisfied. And that's really where our source of business comes from. Hey, we all anticipate further pricing pressure from a variety of areas, you know, including the government. But, you know, as we've mentioned before, this year we guided to stable price, which we realized. Next year, you know, we did sure up a couple contracts, so there will be some price erosion that Gina had mentioned. But I think the important thing, the most important thing, is how healthy the brand is. and, you know, when you look at its demand growth, its ongoing demand growth and what we're seeing, certainly as we finished last year and we're heading into this year, I think we're very confident in the ongoing viability of the brand in the marketplace.

23:06 Great. Thanks for taking my question. Your next question is from Eric Joseph with J.P. Morgan. Your line is open.

23:15 Hi, Eric. Hi, good morning. Thanks for taking the questions. I guess just one following up on, well, really, as you're thinking through potential transactions in the organic GI space, I'm just wondering if there's any further color you might be able to offer in terms of the age of assets that you're looking at in transaction size and whether there's any potential impact on executing that potential transaction from the change of leadership here.

23:48 Eric, could you repeat that question? I don't know about the others, but it broke up a little bit, and it was hard to hear.

23:57 Stuart, can you hear me now? Sorry about this. That's better. Yep, that's a better thing. Okay. Yeah, just wondering if there's any further color on potential transactions that you're thinking about in the organic GI space, particularly around size. and the size of a deal and stage of development in a target asset and whether the change in leadership might have any impact on timing.

24:28 Thanks. So, Tom, why don't you take sort of how you were seeing the sort of organic opportunities in GI and, you know, do you want to certainly jump in with any thoughts you have as well? And Tammi, can I ask a question about strategic direction at the end? Go ahead, Tom. Sure.

24:48 Yes, as both Mark and Gina mentioned, we're really focusing on these serious organic diseases. We've identified a number of assets, as Mike mentioned, and most of these are held by fairly small companies with limited development expertise and essentially no commercial expertise. So obviously, we're really focusing on particularly assets that we can leverage our internal expertise to accelerate time to market. So we're really looking for an asset where there's clear incremental value to be created. So we have a very high bar. We've looked at a number of assets to date. But, you know, we will continue to strive to make sure that, you know, it is the right next move for us as far as, you know, where we're going I mean, obviously, it just builds and it's very complementary to LensS with regard to the commercial model But obviously, Mike and his team bring very deep scientific and medical expertise to make a good choice And then obviously working with Gina's corporate development team to make sure we get the right deal done

25:57 Sure. Thanks, Tom. I mean, I might just continue to add, I don't expect it to impact the leadership change to impact our ability to be able to continue to execute, hopefully, our transactions this year. One, I just have a lot of confidence in Tom, especially working with him over these last seven years plus, in addition to the fact that Julie has stepped up and is giving us additional time as executive chair. So I think the combination has put us in great hands. I would also just remind you that, you know, we just talked a little bit on the last question about, you know, that small amount of revenue and the fluctuations, you know, in API and royalties, for instance, are a milestone payment. But the core business is strong. So the collaboration revenue related to Linzess is incredibly strong and growing year over year.

26:46 And with that fundamental for growing revenue of our core business and cash generation, it just positions us well. and a great place to be able to have the financial capacity to be able to not only afford the upfront related to a development stage asset but also gives us the ability to continue to fund it through development and gives us the P&L space to maintain profitability at the same time.

27:13 Eric, I just want to add one more thought about the readiness of the team to continue to execute. I don't think I've seen Ironwood more ready to keep executing at a high level in the time I've been. Whether you're talking about thriving Lintez Growth, the team, we've got a fantastic commercial team that Thomas built and strengthened actually over the last year. It's executing extremely well. They've got new ideas. They're collaborating well. That's being driven. In the business development standpoint, we've got a fully aligned board with a fully aligned management team. A number of strengths in the team. We've got a clear set of targets that Mike and Tom have talked about. And we've got the resources to focus on the people and the alignment to move fast on that. And the third is that you clearly saw the ability to sort of generate profit and cash in 2020. And that sort of execution and delivery focus is as high as ever.

28:08 So the team is really ready to keep executing. I don't think they're going to miss a beat. They might even step up the beat.

28:16 That's great. Thanks for all the color there. I appreciate you taking the questions. Apologies for the line. Our final question is from Boris Behear with Cullinan. Your line is open.

28:29 Good morning. Hi, Boris. How are you? Can you talk about the trend in gross-to-net discounting and the outlook for that over the next several years?

28:42 Sure, I'll ask Gina to maybe share her thoughts on that, and Tom may want to add some additional color to them, I'm sure. Go ahead, Gina.

28:52 Sure. Hi, Boris. Yes, I'm happy to, especially since 2020 was certainly a great year and one we were quite pleased with. Tom mentioned we originally guided to net sale price for the year. We actually did recognize price. If you think about the year-over-year growth in net sales, It wasn't just due to the strong demand. It was also price appreciation as well. That price appreciation was really due to thoughtful plan design changes that we implemented at the beginning of the year, so the beginning of 2020, where, for instance, we were no longer exclusive on certain plans, but fortunate for us, we didn't see a dip in demand because of those changes. And that was the bulk of the change. We also had some small, I would say unfavorable, small unfavorable adjustments in 2019 related to gross to net, just typical adjustments from time to time.

29:46 But because they weren't repeated in 2020, it did add to some price appreciation for the year. So then, looking forward to 2021, we've obviously, we've guided to and many more. And at the same time, we want to focus on broad payer access with an affordable copay, which is for most of our patients is $30 or less.

30:33 So in order to maintain that broad access, there are times year over year that we need to make changes to make sure that our patients can still access Linset at an affordable price. So that's the change this year. You know, you've heard me say this before, and that I wouldn't expect price appreciation as the norm. I'm pleasantly pleased with 2020, but I wouldn't expect it going forward. I do expect, you know, continued pressure, even pressure throughout 2021. We've guided to the mid-single-digit price erosion, but, you know, payers don't always wait until the contracts expire to knock on the door. So, They'll just continue to monitor it and execute according to plan, right? Focus on demand growth and broad payer access at the same time.

31:21 Great. Go ahead. Of course, just one last thought, and this is really kind of an awakening for us this year. As you know, the far majority of our major plans were preferred unrestricted, meaning we're one of one. And we made a couple of decisions last year to forego the exclusivity and move to basically one of two or even a non-preferred physician. Yet in those plans, we continue to drive growth, like double-digit growth. So I think it offers us some flexibility knowing where we are with these plans as far as other options that maybe we wouldn't have normally had. and I think it just speaks to how strong the brand is with regard to the preference that physicians appear.

32:13 But I completely agree with Tina as we move forward. I think you have to anticipate some price erosion year on year, which is a reason why we have to continue to drive demand.

32:28 Gotcha. That's very helpful. My second question is, I think not too long ago we were talking about a previously prescription option becoming over-the-counter and how that was contributing to your price growth. Is that still out there? Is that still helping prescription growth? And can you provide any updates on that altogether?

32:54 Sure. I think specifically you're talking about the removal of generic drugs. Peg from the prescription market? Is that correct?

33:02 Yeah. Yeah. Yeah. So there's no question at the end of last year we saw, not last year, the year before, 19, we saw this removal and we saw a bolus and influx of prescriptions. But I think the big thing that we saw was the dynamic change in the market because you've just eliminated the market leader, right? as available by prescription. So if they're going to choose a prescription drug, we just eliminate an option, and obviously that had a significant impact in people's choice to Linzess because when patients are frustrated with OTC, the last thing they want is another OTC walking out the door. So not only does Linzess have a great clinical performance profile and level of satisfaction, but now it's one of actually fewer options.

33:53 with the exception of the recent new entrance into the market, which really are not differentiated at all. And I have struggled to gain share, as you know. So we've continued to see Linzess thrive. The far majority of the business is coming directly from the OTC market, which is where it needs to come from. And we're continuing to increase our overall market share in the marketplace. So I think it's this dynamic change of choice which has also helped fuel the growth of Linzess.

34:28 Gotcha. Okay, well, great. Thanks for the detailed answers to my questions. Sure. Our final question is from Jacob Hughes with Wells Fargo Securities. Your line is open.

34:40 Hey, guys. Good morning.

34:43 Morning. Good morning.

34:46 I just have a follow-up question on your guidance. If I just find your revenue, guys, I just take kind of the midpoint of your revenue guidance and take out the $10 million that you mentioned for other, you know, it kind of implies collaboration revenues flattish or up modestly year over year. And I was just wondering, is that point to kind of a reduction on the commercial margin or not? and many more.

35:41 The investments have been, you know, we've been investing fully behind the brands. If you take a look at the numbers this year, I think they're about $10 million less year over year. So I think, you know, we can still fully invest behind the brand and make more thoughtful investments with a higher ROI as well. I would go back to thinking about it as we guide it to growing live death sales of 3% to 5% for the year. roughly same level of investment. And just remind you that obviously we get 50% of that increase, right?

36:16 Okay. All right. Thank you.

36:17 All right. Hopefully that's helpful. We have no further questions at this time. I turn the call back to presenters for closing remarks.

36:29 Tom, I just want, and the team again, I just want to thank all of you for great work in 2020. and I want to wish you the best of luck, Tom, as you move into the interim CEO and, of course, the whole team to continue their great work and success. As I said in my remarks, I'm full confidence of everything moving forward. And, Thomas, I'll give you a chance to have the last word as you're going to be moving into the interim CEO role. Thanks for all your support over the last two years.

36:58 Sure. And, Mark, I know I speak on behalf of the board and certainly the management team. Thank you for having me. Thank you for having me. and many more.

38:04 and certainly we have a very strong expert team to move forward. So thank you for everything and I look forward to the upcoming year and making a very good decision with the board on the future CEO. Thank you.

38:24 Thanks, operator. That's it for us. This concludes today's conference call. You may now disconnect.

Follow Ironwood Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Boris Behear

Analyst, Cullinan Research

Mike Shetzline

Chief Medical Officer

Meredith Faya

Director of Investor Relations

Gina Konselman

Chief Financial Officer

Tom McCourt

President and Interim CEO

Jacob Hughes

Analyst, Wells Fargo Securities

Eric Joseph

Analyst, J.P. Morgan

Mark Mallon

Chief Executive Officer

More from Ironwood Pharmaceuticals, Inc.